Biological variations in depression and anxiety between east and west

CNS Neuroscience and Therapeutics

Volumn 15, Issue 3, 2009, Pages 283-294

  Chen, Po Yu ^a,b   Wang, Sheng Chang ^b   Poland, Russell E ^c   Lin, Keh Ming ^b,d  

^a TAIPEI CITY HOSPITAL   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c MEHARRY MEDICAL COLLEGE   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

Biological marker; Culture; Ethnicity; Pharmacodynamics; Pharmacogenetics; Pharmacokinetics; Taiwan; Variation

Indexed keywords

ADINAZOLAM; ALPRAZOLAM; AMITRIPTYLINE; BENZODIAZEPINE; CHLORPROMAZINE; CLOMIPRAMINE; CLOZAPINE; DESIPRAMINE; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; LITHIUM; MOOD STABILIZER; NORFLUOXETINE; NORTRIPTYLINE; OPIATE; PAROXETINE; PERPHENAZINE; PLACEBO; PROPRANOLOL; PSYCHOTROPIC AGENT; RISPERIDONE; SERTINDOLE; SERTRALINE; THIORIDAZINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE;

ANTICHOLINERGIC EFFECT; ANXIETY DISORDER; AREA UNDER THE CURVE; BEHAVIOR; CLINICAL TRIAL; CULTURAL FACTOR; DELIRIUM; DEPRESSION; DIET; DISEASE MARKER; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG RESPONSE; ENVIRONMENTAL FACTOR; ETHNIC DIFFERENCE; GENE EXPRESSION; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LOW DRUG DOSE; MOOD DISORDER; PHARMACOGENETICS; RECEPTOR GENE; REVIEW; SEDATION; SIDE EFFECT; SLEEP PATTERN; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TREMOR; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ANXIETY DISORDERS; ASIAN CONTINENTAL ANCESTRY GROUP; CROSS-CULTURAL COMPARISON; DEPRESSIVE DISORDER; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC VARIATION; HUMANS;

EID: 68849093673     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2009.00093.x     Document Type: Review

References (100)

1. Lin KM, Lau JK, Smith R, Phillips P, Antal E, Poland RE. Comparison of alprazolam plasma levels in normal Asian and Caucasian male volunteers. Psychopharmacology (Berl) 1988 96 : 365 369.
2. Kalow W, Otton SV, Kadar D, Endrenyi L, Inaba T. Ethnic difference in drug metabolism: Debrisoquine 4-hydroxylation in Caucasians and Orientals. Can J Physiol Pharmacol 1980 58 : 1142 1144.
3. Lawson WB. Racial and ethnic factors in psychiatric research. Hosp Community Psychiatry 1986 37 : 50 54.
4. Lin KM. Biological differences in depression and anxiety across races and ethnic groups. J Clin Psychiatry 2001 62 (Suppl 13 13 19 discussion 20-21.
5. Takahashi R. Lithium treatment in affective disorders: Therapeutic plasma level. Psychopharmacol Bull 1979 15 : 32 35.
6. Yamashita I, Asano Y. Tricyclic antidepressants: Therapeutic plasma level. Psychopharmacol Bull 1979 15 : 40 41.
7. Matsuda KT, Cho MC, Lin KM, Smith MW, Young AS, Adams JA. Clozapine dosage, serum levels, efficacy, and side-effect profiles: A comparison of Korean-American and Caucasian patients. Psychopharmacol Bull 1996 32 : 253 257.
8. Darmansjah I, Muchtar A. Dose-response variation among different populations. Clin Pharmacol Ther 1992 52 : 449 452.
9. Escobar JI, Tuason VB. Antidepressant agents - A cross-cultural study. Psychopharmacol Bull 1980 16 : 49 52.
10. Marcos LR, Cancro R. Pharmacotherapy of Hispanic depressed patients: Clinical observations. Am J Psychother 1982 36 : 505 512.
11. World Health Organization. Dose effects of antidepressant medication in different populations. A World Health Organization Collaborative Study. J Affect Disord 1986 2 (Suppl S1 S67.
12. Versiani M OA, Mazzotti G, Ospina J, Davila J, Mata S, Pacheco A, Plewes J, Tamura R, Palacios M. A double-blind comparison of fluoxetine and amitriptyline in the treatment of major depression with associated anxiety ('anxious depression'). Cross Cultural Psychiatry 1999 : 249 258.
13. Overall JE, Hollister LE, Kimbell I Jr., Shelton J. Extrinsic factors influencing responses to psychotherapeutic drugs. Arch Gen Psychiatry 1969 21 : 89 94.
14. Henry BW, Overall JE, Markette JR. Comparison of major drug therapies for alleviation of anxiety and depression. Dis Nerv Syst 1971 32 : 655 667.
15. Raskin A, Crook TH. Antidepressants in black and white inpatients. Differential response to a controlled trial of chlorpromazine and imipramine. Arch Gen Psychiatry 1975 32 : 643 649.
16. Livingston RL, Zucker DK, Isenberg K, Wetzel RD. Tricyclic antidepressants and delirium. J Clin Psychiatry 1983 44 : 173 176.
17. Hong Ng C, Norman TR, Naing KO, et al. A comparative study of sertraline dosages, plasma concentrations, efficacy and adverse reactions in Chinese versus Caucasian patients. Int Clin Psychopharmacol 2006 21 : 87 92.
18. Wagner GJ, Maguen S, Rabkin JG. Ethnic differences in response to fluoxetine in a controlled trial with depressed HIV-positive patients. Psychiatr Serv 1998 49 : 239 240.
19. Roy-Byrne PP, Perera P, Pitts CD, Christi JA. Paroxetine response and tolerability among ethnic minority patients with mood or anxiety disorders: A pooled analysis. J Clin Psychiatry 2005 66 : 1228 1233.
20. Kishimoto A, Hollister LE. Nortriptyline kinetics in Japanese and Americans. J Clin Psychopharmacol 1984 4 : 171 172.
21. Lewis P, Rack PH, Vaddadi KS, Allen JJ. Ethnic differences in drug response. Postgrad Med J 1980 56 (Suppl 1 46 49.
22. Rudorfer MV. Pharmacokinetics of psychotropic drugs in special populations. J Clin Psychiatry 1993 54 (Suppl 50 54 discussion 5-6.
23. Schneider L, Pawluczyk B, Dopheide J, Lyness SA, Suckow RF, Cooper TB. Ethnic differences in nortriptyline metabolism (New Research Program and Abstracts, p 206). Paper presented at the annual meeting of the American Psychiatric Association. New Orleans, LA 1991.
24. Ajir K, Smith M, Lin KM, Fleishaker JC, Chambers JH, Anderson D, Nuccio C, Zheng YP. The pharmacokinetics and pharmacodynamics of adinazolam: Multi-ethnic comparisons. Psychopharmacology (Berl) 1997 129 : 265 270.
25. Ghoneim MM, Korttila K, Chiang CK, Jacobs L, Schoenwald RD, Mewaldt SP, Kayaba KO. Diazepam effects and kinetics in Caucasians and Orientals. Clin Pharmacol Ther 1981 29 : 749 756. (Pubitemid 11006722)
26. Kumana CR, Lauder IJ, Chan M, Ko W, Lin HJ. Differences in diazepam pharmacokinetics in Chinese and white Caucasians - Relation to body lipid stores. Eur J Clin Pharmacol 1987 32 : 211 215.
27. You JS, Hu SY, Chen B, Zhang HG. Serotonin transporter and tryptophan hydroxylase gene polymorphisms in Chinese patients with generalized anxiety disorder. Psychiatr Genet 2005 15 : 7 11.
28. Ziegler VE, Biggs JT. Tricyclic plasma levels. Effect of age, race, sex, and smoking. Jama 1977 238 : 2167 2169.
29. Rudorfer MV, Robins E. Amitriptyline overdose: Clinical effects on tricyclic antidepressant plasma levels. J Clin Psychiatry 1982 43 : 457 460.
30. Zhou Z, Roy A, Lipsky R, Kuchipudi K, Zhu G, Taubman J, Virkkunen M, Goldman D. Haplotype-based linkage of tryptophan hydroxylase 2 to suicide attempt, major depression, and cerebrospinal fluid 5-hydroxyindoleacetic acid in 4 populations. Arch Gen Psychiatry 2005 62 : 1109 1118.
31. Cepeda MS, Farrar JT, Roa JH, Boston R, Meng QC, Ruiz F, Carr DB, Strom BL. Ethnicity influences morphine pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2001 70 : 351 361.
32. Zhou HH, Sheller JR, Nu H, Wood M, Wood AJ. Ethnic differences in response to morphine. Clin Pharmacol Ther 1993 54 : 507 513.
33. Chang S PG, Yang Y, Yeh E, Davis JM. Lithium pharmacokinetics: Inter-racial comparison. Presented at the 138th Annual Meeting of the American Psychiatric Association 1985.
34. Lim L, Ng TP, Chua HC, Chiam PC, Won V, Lee T, Fong C, Kua EH. Generalised anxiety disorder in Singapore: Prevalence, co-morbidity and risk factors in a multi-ethnic population. Soc Psychiatry Psychiatr Epidemiol 2005 40 : 972 979.
35. Yang YY. Prophylactic efficacy of lithium and its effective plasma levels in Chinese bipolar patients. Acta Psychiatr Scand 1985 71 : 171 175.
36. Hu WH, Lee CF, Yang YY, Tseng YT. Imipramine plasma levels and clinical response. Bull Chin Social Neurosci Psychiatr 1983 9 : 40 49.
37. Dalen P, Dahl ML, Ruiz ML, Nordin J, Bertilsson L. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 1998 63 : 444 452.
38. Fukuda T, Nishida Y, Imaoka S, Hiroi T, Naohara M, Funae Y, Azuma J. The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6. Arch Biochem Biophys 2000 380 : 303 308.
39. Veefkind AH, Haffmans PM, Hoencamp E. Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit 2000 22 : 202 208.
40. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996 278 : 441 446.
41. Masimirembwa CM, Hasler JA. Genetic polymorphism of drug metabolising enzymes in African populations: Implications for the use of neuroleptics and antidepressants. Brain Res Bull 1997 44 : 561 571.
42. Luo HR, Aloumanis V, Lin KM, Gurwitz D, Wan YJ. Polymorphisms of CYP2C19 and CYP2D6 in Israeli ethnic groups. Am J Pharmacogenomics 2004 4 : 395 401.
43. Gough AC, Miles JS, Spurr NK, Moss JE, Gaedigk A, Eichelbaum M, Wolf CR. Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 1990 347 : 773 776.
44. Wang SL, Huang JD, Lai MD, Liu BH, Lai ML. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: Polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 1993 53 : 410 418.
45. DeVane CL. Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry 1994 55 (Suppl 38 45 discussion 6-7.
46. Ereshefsky L, Dugan D. Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: Focus on venlafaxine. Depress Anxiety 2000 12 (Suppl 1 30 44.
47. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994 269 : 15419 15422.
48. Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, Evans DA. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997 7 : 59 64.
49. Luo HR, Poland RE, Lin KM, Wan YJ. Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: A cross-ethnic comparative study. Clin Pharmacol Ther 2006 80 : 33 40.
50. Rashid TJ, Martin U, Clarke H, Waller DG, Renwick AG, George CF. Factors affecting the absolute bioavailability of nifedipine. Br J Clin Pharmacol 1995 40 : 51 58.
51. Sowunmi A, Rashid TJ, Akinyinka OO, Renwick AG. Ethnic differences in nifedipine kinetics: Comparisons between Nigerians, Caucasians and South Asians. Br J Clin Pharmacol 1995 40 : 489 493.
52. Branch RA, Salih SY, Homeida M. Racial differences in drug metabolizing ability: A study with antipyrine in the Sudan. Clin Pharmacol Ther 1978 24 : 283 286. (Pubitemid 8396507)
53. Allen JJ, Rack PH, Vaddadi KS. Differences in the effects of clomipramine on English and Asian volunteers. Preliminary report on a pilot study. Postgrad Med J 1977 53 (Suppl 4 79 86.
54. Fraser HS, Mucklow JC, Bulpitt CJ, Kahn C, Mould G, Dollery CT. Environmental factors affecting antipyrine metabolism in London factory and office workers. Br J Clin Pharmacol 1979 7 : 237 243.
55. Pollock BG, Ferrell RE, Mulsant BH, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000 23 : 587 590.
56. Rausch JL, Johnson ME, Fei YJ, Li JQ, Shendarkar N, Hobby HM, Ganapathy V, Leiback FH. Initial conditions of serotonin transporter kinetics and genotype: Influence on SSRI treatment trial outcome. Biol Psychiatry 2002 51 : 723 732.
57. Serretti A, Zanardi R, Rossini D, Cusin C, Lilli R, Smeraldi E. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry 2001 6 : 586 592.
58. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998 3 : 508 511.
59. Zanardi R, Serretti A, Rossini D, Franchini L, Cusin C, Lattuada E, Dotoli D, Smeraldi E. Factors affecting fluvoxamine antidepressant activity: Influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry 2001 50 : 323 330.
60. Greenberg BD, McMahon FJ, Murphy DL. Serotonin transporter candidate gene studies in affective disorders and personality: Promises and potential pitfalls. Mol Psychiatry 1998 3 : 186 189.
61. Jonsson EG, Nothen MM, Gustavsson JP, Neidt H, Bunzel R, Propping P, Sedvall GC. Polymorphisms in the dopamine, serotonin, and norepinephrine transporter genes and their relationships to monoamine metabolite concentrations in CSF of healthy volunteers. Psychiatry Res 1998 79 : 1 9.
62. Mundo E, Walker M, Cate T, Macciardi F, Kennedy JL. The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: Preliminary findings. Arch Gen Psychiatry 2001 58 : 539 544.
63. Perlis RH, Mischoulon D, Smoller JW, et al. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biological Psychiatry 2003 54 : 879 883.
64. Kim K, Johnson JA, Derendorf H. Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol 2004 44 : 1083 1105.
65. Stein MB, Schork NJ, Gelernter J. A polymorphism of the beta1-adrenergic receptor is associated with low extraversion. Biol Psychiatry 2004 56 : 217 224.
66. Grossman MH, Emanuel BS, Budarf ML. Chromosomal mapping of the human catechol-O-methyltransferase gene to 22q11.1->q11.2. Genomics 1992 12 : 822 825.
67. Ma MK, Woo MH, McLeod HL. Genetic basis of drug metabolism. Am J Health Syst Pharm 2002 59 : 2061 2069.
68. Palmatier MA, Kang AM, Kidd KK. Global variation in the frequencies of functionally different catechol-O-methyltransferase alleles. Biol Psychiatry 1999 46 : 557 567.
69. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Kirmayer LJ, Lepine JP, Lin KM, Tajima O, Ono Y. Consensus statement on transcultural issues in depression and anxiety from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 2001 62 (Suppl 13 47 55. (Pubitemid 32574874)
70. Henderson AS, Korten AE, Jorm AF, Jacomb PA, Christensen H, Rodgers B, Tan S, Esteal S. COMT and DRD3 polymorphisms, environmental exposures, and personality traits related to common mental disorders. Am J Med Genet 2000 96 : 102 107.
71. Horowitz R, Kotler M, Shufman E, Aharoni S, Kremer I, Cohen H, Ebstein RP. Confirmation of an excess of the high enzyme activity COMT val allele in heroin addicts in a family-based haplotype relative risk study. Am J Med Genet 2000 96 : 599 603.
72. Kotler M, Barak P, Cohen H, Averbuch IE, Grinshpoon A, Gritsenko I, Nemanov L, Ebstein RP. Homicidal behavior in schizophrenia associated with a genetic polymorphism determining low catechol O-methyltransferase (COMT) activity. Am J Med Genet 1999 88 : 628 633.
73. Takeuchi T, Fukuda K, Sasaki Y, Inugami M, Murphy TI. Factors related to the occurrence of isolated sleep paralysis elicited during a multi-phasic sleep-wake schedule. Sleep 2002 25 : 89 96.
74. Thase ME, Simons AD, Reynolds CF 3rd. Abnormal electroencephalographic sleep profiles in major depression: Association with response to cognitive behavior therapy. Arch Gen Psychiatry 1996 53 : 99 108.
75. Kupfer DJ. Sleep research in depressive illness: Clinical implications - A tasting menu. Biol Psychiatry 1995 38 : 391 403.
76. Mendlewicz J, Kerkhofs M. Sleep electroencephalography in depressive illness. A collaborative study by the World Health Organization. Br J Psychiatry 1991 159 : 505 509.
77. Poland RE, Rao U, Lutchmansingh P, McCracken JT, Lesser IM, Edwards C, Lin KM. REM sleep in depression is influenced by ethnicity. Psychiatry Res 1999 88 : 95 105.
78. Takeuchi T, Miyasita A, Sasaki Y, Inugami M, Fukuda K. Isolated sleep paralysis elicited by sleep interruption. Sleep 1992 15 : 217 225.
79. Dahlitz M, Parkes JD. Sleep paralysis. Lancet 1993 341 : 406 407.
80. Ness RC. The Old Hag phenomenon as sleep paralysis: A biocultural interpretation. Cult Med Psychiatry 1978 2 : 15 39.
81. Bell CC, Shakoor B, Thompson B, Dew D, Hughley E, Mays R, Shorter-Gooden K. Prevalence of isolated sleep paralysis in black subjects. J Natl Med Assoc 1984 76 : 501 508.
82. Paradis CM, Friedman S, Hatch M. Isolated sleep paralysis in African Americans with panic disorder. Cult Divers Ment Health 1997 3 : 69 76.
83. Ohaeri JU. The prevalence of isolated sleep paralysis among a sample of Nigerian civil servants and undergraduates. Afr J Med Med Sci 1997 26 : 43 45.
84. Awadalla A, Al-Fayez G, Harville M, Arikawa H, Tomeo ME, Templer DI, Underwood R. Comparative prevalence of isolated sleep paralysis in Kuwaiti, Sudanese, and American college students. Psychol Rep 2004 95 : 317 322.
85. Hinton DE, Pich V, Chhean D, Pollack MH. 'The ghost pushes you down': Sleep paralysis-type panic attacks in a Khmer refugee population. Transcult Psychiatry 2005 42 : 46 77.
86. Fukuda K, Miyasita A, Inugami M, Ishihara K. High prevalence of isolated sleep paralysis: Kanashibari phenomenon in Japan. Sleep 1987 10 : 279 286.
87. Wing YK, Lee ST, Chen CN. Sleep paralysis in Chinese: Ghost oppression phenomenon in Hong Kong. Sleep 1994 17 : 609 613.
88. Ohayon MM, Shapiro CM. Sleep disturbances and psychiatric disorders associated with posttraumatic stress disorder in the general population. Compr Psychiatry 2000 41 : 469 478.
89. Abrams MP, Mulligan AD, Carleton RN, Asmundson GJ. Prevalence and correlates of sleep paralysis in adults reporting childhood sexual abuse. J Anxiety Disord 2008 22 : 1535 1541.
90. Hinton DE, Pich V, Chhean D, Pollack MH, McNally RJ. Sleep paralysis among Cambodian refugees: Association with PTSD diagnosis and severity. Depress Anxiety 2005 22 : 47 51.
91. Bell CC, Hildreth CJ, Jenkins EJ, Carter C. The relationship of isolated sleep paralysis and panic disorder to hypertension. J Natl Med Assoc 1988 80 : 289 294.
92. Paradis CM, Friedman S. Sleep paralysis in African Americans with panic disorder. Transcult Psychiatry 2005 42 : 123 134.
93. Otto MW, Simon NM, Powers M, Hinton D, Zalta AK, Pollack MH. Rates of isolated sleep paralysis in outpatients with anxiety disorders. J Anxiety Disord 2006 20 : 687 693.
94. Mellman TA, Aigbogun N, Graves RE, Lawson WB, Alim TN. Sleep paralysis and trauma, psychiatric symptoms and disorders in an adult African American population attending primary medical care. Depress Anxiety 2008 25 : 435 440.
95. Ramsawh HJ, Raffa SD, White KS, Barlow DH. Risk factors for isolated sleep paralysis in an African American sample: A preliminary study. Behav Ther 2008 39 : 386 397.
96. Staner L, Linkowski P, Mendlewicz J. Biological markers as classifiers for depression: A multivariate study. Prog Neuropsychopharmacol Biol Psychiatry 1994 18 : 899 914.
97. Escobar JI. Are results on the dexamethasone suppression test affected by ethnic background? Am J Psychiatry 1985 142 : 268.
98. Poland RE, Rubin RT, Lesser IM, Lane LA, Hart PJ. Neuroendocrine aspects of primary endogenous depression. II. Serum dexamethasone concentrations and hypothalamic-pituitary-adrenal cortical activity as determinants of the dexamethasone suppression test response. Arch Gen Psychiatry 1987 44 : 790 795.
99. Coppen A, Harwood J, Wood K. Depression, weight loss and the dexamethasone suppression test. Br J Psychiatry 1984 145 : 88 90.
100. de la Fuente JR, Sepulveda Amor J. Does ethnicity affect DST results? Am J Psychiatry 1986 143 : 275 276.